Psilocybin
Compass Pathways’ Stock Soars as COMP360 Receives Patent Victory
Compass Pathways’ COMP360 has just received additional support for its IP strategy, with the US Patent and Trademark Office upholding patent protections…
Compass Pathways’ COMP360 has just received additional support for its IP strategy, with the US Patent and Trademark Office upholding patent protections on the compound.
Compass’ COMP360 is the psilocybin molecule with the most advanced clinical trial in the psychedelic medicine space (currently in Phase 3). Compass has been both praised for its leadership in advancing psychedelics with the FDA and criticized for what some believe is an unreasonable approach to patents, with several patent challenges brought against it.
Despite this, Compass has won its recent patent challenges and added another win to patent catalog today. The patent office has reaffirmed decisions to uphold ‘257 Patent and ‘259 Patent, key patents covering COMP360 crystalline psilocybin polymorph A, the polymorph being used in the Company’s phase 3 clinical trials.
With IP protection a key to investor confidence, Compass’ stock closed the day up almost 10%.
COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office
- PTAB rejects two requests for rehearing of the USPTO’s decision denying institution of post-grant review (PGR) of U.S. patent numbers 10,947,257 (‘257 Patent) and 10,954,259 (‘259 Patent).
- In June 2022, the PTAB denied institution of the PGRs finding the challenger failed to establish that any of the claims of ‘257 Patent and ‘259 Patent are unpatentable.
LONDON, June 06, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation, announced today that the US Patent Trial and Appeal Board (PTAB) reaffirmed decisions to uphold ‘257 Patent and ‘259 Patent, key patents covering COMP360 crystalline psilocybin polymorph A, the polymorph being used in the Company’s phase 3 clinical trials. The decision can be found on the USPTO website at: https://developer.uspto.gov/ptab-web/#/search/documents?proceedingNumber=PGR2022-00018.
Kabir Nath, COMPASS Pathways Chief Executive Officer, stated, “COMPASS is pleased with the PTAB’s decision to uphold two important US patents covering the Company’s crystalline psilocybin polymorph A. Patents are a key element of our overall commercial protection of COMP360, which is central to our work in developing innovative treatments for therapeutic areas of significant unmet medical need, including our lead program in treatment-resistant depression.”
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP 360 psilocybin therapy in TRD, the largest randomised, controlled, double-blind psilocybin therapy clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also conducting phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellbeing. www.compasspathways.com
The post Compass Pathways’ Stock Soars as COMP360 Receives Patent Victory appeared first on Microdose.
psilocybin psychedelic therapy breakthrough therapy depression ptsd psychedelics nasdaq compass fda-
Psychedelics7 days ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Psilocybin6 days ago
Are Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week ago
Numinus reports declining revenue as the company restructures
-
Law & Regulation7 days ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psychedelics7 days ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics7 days ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Psychedelics6 days ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation5 days ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights